Consulta: creatorFacets:"Sternberg,C."
Registros recuperados: 3
Data/hora: 10/06/2024 18:20:44

Caspase dependence of the death of neonatal retinal ganglion cells induced by axon damage and induction of autophagy as a survival mechanism
Provedor de dados: 56
Autores: Sternberg,C.; Benchimol,M.; Linden,R.
We examined the degeneration of post-mitotic ganglion cells in ex-vivo neonatal retinal explants following axon damage. Ultrastructural features of both apoptosis and autophagy were detected. Degenerating cells reacted with antibodies specific for activated caspase-3 or -9, consistent with the presence of caspase activity. Furthermore, peptidic inhibitors of caspase-9, -6 or -3 prevented cell death (100 µM Ac-LEDH-CHO, 50 µM Ac-VEID-CHO and 10 µM Z-DEVD-fmk, respectively). Interestingly, inhibition of autophagy by 7-10 mM 3-methyl-adenine increased the rate of cell death. Immunohistochemistry data, caspase activation and caspase inhibition data suggest that axotomy of neonatal retinal ganglion cells triggers the intrinsic apoptotic pathway, which, in turn,...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Apoptosis; Autophagy; Caspases; Retina; Central nervous system.
Ano: 2010
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010001000005

The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC)
Provedor de dados: 56
Autores: Fernandes,G.S.; Sternberg,C.; Lopes,G.; Chammas,R.; Gifoni,M.A.C.; Gil,R.A.; Araujo,D.V.
A biosimilar is a biologic product that is similar to a reference biopharmaceutical product, the manufacturing process of which hinders the ability to identically replicate the structure of the original product, and therefore, it cannot be described as an absolute equivalent of the original medication. The currently available technology does not allow for an accurate copy of complex molecules, but it does allow the replication of similar molecules with the same activity. As biosimilars are about to be introduced in oncology practice, these must be evaluated through evidence-based medicine. This manuscript is a position paper, where the Brazilian Society of Clinical Oncology (SBOC) aims to describe pertinent issues regarding the approval and use of...
Tipo: Info:eu-repo/semantics/other
Palavras-chave: Immunobiologicals; Therapeutic antibodies; Biosimilar; Cancer management; Access.
Ano: 2018
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018000300401

Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer
Provedor de dados: 56
Autores: de Almeida,V.H.; de Melo,A.C.; Meira,D.D.; Pires,A.C.; Nogueira-Rodrigues,A.; Pimenta-Inada,H.K.; Alves,F.G.; Moralez,G.; Thiago,L.S.; Ferreira,C.G.; Sternberg,C.
Cervical cancer is a public health problem and the molecular mechanisms underlying radioresistance are still poorly understood. Here, we evaluated the modulation of key molecules involved in cell proliferation, cell cycle and DNA repair in cervical cancer cell lines (CASKI and C33A) and in malignant tissues biopsied from 10 patients before and after radiotherapy. The expression patterns of epidermal growth factor receptor (EGFR), excision repair cross-complementation group 1 (ERCC1) and p53 were evaluated in cancer cell lines by quantitative PCR and western blotting, and in human malignant tissues by immunohistochemistry. The mutation status of TP53 gene was evaluated by direct sequencing. Among cell lines, absent or weak modulations of EGFR, ERCC1 and p53...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Cervical cancer; Radiotherapy; Epidermal growth factor receptor (EGFR); P53; Excision repair cross-complementation group 1 (ERCC1).
Ano: 2018
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2018000100608